Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial)

Catheterization and Cardiovascular Interventions

Volumn 83, Issue 3, 2014, Pages 418-424

  Stiermaier, Thomas ^a   Heinz, Anja ^a   Schloma, Denis ^a   Kleinertz, Klaus ^b   Dänschel, Wilfried ^b   Erbs, Sandra ^a   Linke, Axel ^a   Boudriot, Enno ^a   Lauer, Bernward ^c   Schuler, Gerhard ^a   Thiele, Holger ^a   Desch, Steffen ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Heart Center   (Germany)

^c Zentralklinik Bad Berka ^*  (Germany)

Author keywords

coronary artery disease; drug eluting stent; paclitaxel; polymer free; sirolimus

Indexed keywords

CORONARY ARTERY DISEASE; DRUG-ELUTING STENT; PACLITAXEL; POLYMER-FREE; SIROLIMUS;

AGED; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; FEMALE; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; POLYMERS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893812350     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25131     Document Type: Article

References (18)

1. Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane A, Byrne R, Williams D, Slater J, Cutlip D, Feit F,. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: Mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ 2012; 345: e5170.
2. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB,. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
3. Jaffe R, Strauss BH,. Late and very late thrombosis of drug-eluting stents: Evolving concepts and perspectives. J Am Coll Cardiol 2007; 50: 119-127.
4. Garg S, Serruys PW,. Coronary stents. J Am Coll Cardiol 2010; 56: S1-S42.
5. Finn A, Nakazawa G, Joner M, Kolodgie F, Mont E, Gold H, Virmani R,. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510.
6. Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, Graf I, Renke-Gluszko M, Behnisch B, Dirschinger J, Wintermantel E, Schömig A,. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 2005; 26: 1475-1481.
7. Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O, Pache J, Wessely R, Schomig A, Kastrati A,. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008; 29: 1975-1982.
8. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schomig A,. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006; 113: 273-279.
9. Ruef J, Storger H, Schwarz F, Haase J,. Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions. Catheter Cardiovasc Interv 2008; 71: 333-339.
10. Ruef J, Storger H, Schwarz F, Haase J,. Increased restenosis rates 12 months after coronary implantation of the sirolimus-eluting YUKON-choice stent compared to the paclitaxel-eluting TAXUS Stent. Clin Cardiol 2010; 33: E33-E38.
11. King L, Byrne R, Mehilli J, Schomig A, Kastrati A, Pache J,. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: Final results of the intracoronary stenting and angiographic restenosis-Test Equivalence Between Two Drug-Eluting Stents (ISAR-TEST) Trial. Catheter Cardiovasc Interv 2013; 81: E23-E28.
12. Byrne RA, Kufner S, Tiroch K, Massberg S, Laugwitz KL, Birkmeier A, Schulz S, Mehilli J,. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 2009; 95: 1489-1494.
13. Desch S, Schloma D, Moebius-Winkler S, Erbs S, Gielen S, Linke A, Yu J, Lauer B, Kleinertz K, Dänschel W, Schuler G, Thiele H,. Randomized comparison of a ploymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: The LIPSIA Yukon trial. JACC Cardiovac Interv 2011; 4: 452-459.
14. Turco MA, Ormiston JA, Popma JJ, Mandinov L, O'Shaughnessy CD, Mann T, McGarry TF, Wu CJ, Chan C, Webster MW, Hall JJ, Mishkel GJ, Cannon LA, Baim DS, Koglin J,. Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: The pivotal TAXUS ATLAS trial. J Am Coll Cardiol 2007; 49: 1676-1683.
15. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME,. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
16. Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S, Behnisch B, Schratzenstaller T, Renke-Gluszko M, Stöver M, Wintermantel E, Kastrati A, Schömig A,. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 2005; 25: 748-753.
17. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW,. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
18. Urban P, Abizaid A, Chevalier B, Greene S, Meredith I, Morice MC, Pocock S,. Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy. Am Heart J 2013; 165: 704-709.